Lupin announced the launch of Posaconazole Delayed-Release Tablets, 100 mg, after its alliance partner AET Pharma US (part of Tiefenbacher Group) received approval for its ANDA from the United States Food and Drug Administration (USFDA)
Posaconazole Delayed-Release Tablets, 100 mg, are the generic equivalent of Noxafil Delayed Release Tablets, 100 mg, of Merck Sharp & Dohme Corp,.
These tablets are indicated for prophylaxis of invasive Aspergillus and Candida infections in patients who are at high risk of developing these infections due to being severely immunocompromised, such as hematopoietic stem cell transplant (HSCT) recipients with graft-versus-host disease (GVHD) or those with hematologic malignancies with prolonged neutropenia from chemotherapy.
Posaconazole Delayed-Release Tablets, 100 mg (RLD: Noxafil) had estimated annual sales of $186 million in the US (IQVIA MAT December 2020).
Go to main website, click here
Subscribe for daily free updates, click here
For daily free updates on WhatsApp, click here